Replies to post #187792 on Biotech Values

[DewDiligence]

LLY drops Peglispro basal-insulin program:

http://finance.yahoo.com/news/lilly-ends-basal-insulin-peglispro-130000789.html

This decision is unsurprising given the finding of liver toxicity in Feb 2015 (#msg-111084023).